<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492607</url>
  </required_header>
  <id_info>
    <org_study_id>M18LORD</org_study_id>
    <secondary_id>2014-04</secondary_id>
    <secondary_id>EORTC-1401</secondary_id>
    <nct_id>NCT02492607</nct_id>
  </id_info>
  <brief_title>Management of Low-risk (Grade I and II) DCIS</brief_title>
  <acronym>LORD</acronym>
  <official_title>Management of Low Risk Ductal Carcinoma in Situ (Low-risk DCIS): a Non-randomized, Multicenter, Non-inferiority Trial, Between Standard Therapy Approach Versus Active Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Borstkanker Onderzoek Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A substantial number of DCIS lesions will never form a health hazard, particularly if it&#xD;
      concerns slow-growing low-risk DCIS (grade I and II). This implies that many women might be&#xD;
      unnecessarily going through intensive treatment resulting in a decrease in quality of life&#xD;
      and an increase in health care costs, without any survival benefit.&#xD;
&#xD;
      The LORD (LOw Risk DCIS) study is a non-randomized, international, multicenter, phase III&#xD;
      non-inferiority trial, and aims to determine whether screen-detected low-risk DCIS can safely&#xD;
      be managed by an active surveillance strategy or that the conventional treatment, being&#xD;
      either WLE alone, WLE + RT, or mastectomy, and possibly HT, should remain the standard of&#xD;
      care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background of the study:&#xD;
&#xD;
      The introduction of population-based breast cancer screening and implementation of digital&#xD;
      mammography have led to an increased incidence of ductal carcinoma in situ (DCIS) without a&#xD;
      decrease in the incidence of advanced breast cancer. This suggests DCIS overdiagnosis exists.&#xD;
      We hypothesize that asymptomatic, low-risk DCIS (grade I and II DCIS) can safely be managed&#xD;
      by active surveillance. If progression to invasive breast cancer would still occur, this will&#xD;
      be lowgrade and hormone receptor positive with excellent survival rates. Also,&#xD;
      breast-conserving treatment will still be an option, if no prior radiotherapy has been&#xD;
      applied. It also may save many low-risk DCIS patients from intensive treatment.&#xD;
&#xD;
      Objective of the study:&#xD;
&#xD;
      The primary end-point is ipsilateral invasive breast tumor-free rate at 10 years.&#xD;
&#xD;
      Secondary end-points are among others: overall survival, breast cancer-specific survival,&#xD;
      mastectomy rate and patient reported outcomes. To determine whether low- risk DCIS can safely&#xD;
      (measured by ipsilateral invasive breast cancer rate at 10 years) be managed by an active&#xD;
      surveillance strategy or if the conventional treatment, being either wide local excision&#xD;
      (WLE) only, WLE plus radiotherapy or mastectomy, possibly followed by hormonal therapy, will&#xD;
      remain the standard of care.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Phase III, open-label, non-inferiority, multi-center, non-randomized clinical trial. By&#xD;
      patient's preference, women will be included into one of the following arms: active&#xD;
      surveillance or standard treatment according to local policy, being either WLE alone, WLE&#xD;
      plus radiotherapy or mastectomy, possibly followed by hormonal therapy. The same follow-up&#xD;
      scheme will be applied in both study arms, i.e. annual mammography for a period of five years&#xD;
      and an additional two mammograms at year seven and ten.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2017</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ipsilateral invasive breast cancer-free rate at 10 years</measure>
    <time_frame>10 years from inclusion</time_frame>
    <description>Ipsilateral invasive breast cancer-free rate at 10 years (both therapeutic policies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to ipsilateral grade III DCIS</measure>
    <time_frame>from inclusion to the development of a new ipsilateral DCIS, up to 10 years</time_frame>
    <description>Time to ipsilateral grade III DCIS, both therapeutic policies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to contralateral DCIS</measure>
    <time_frame>from inclusion to the development of a new contralateral DCIS, up to 10 years</time_frame>
    <description>Time to contralateral DCIS, both therapeutic policies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to contralateral invasive breast cancer</measure>
    <time_frame>from inclusion to the development of a contralateral invasive breast cancer, up to 10 years</time_frame>
    <description>Time to contralateral invasive breast cancer,, both therapeutic policies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to failure of active surveillance strategy</measure>
    <time_frame>from inclusion to the time to patients received standard treatment, up to 10 years</time_frame>
    <description>Time to failure of active surveillance strategy, i.e. time to crossover to standard treatment, due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastases free interval</measure>
    <time_frame>from inclusion to the time of invasive distant metastases or death due to breast cancer, up to 10 years</time_frame>
    <description>Distant metastases free interval,both therapeutic policies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from inclusion to the time of death, during 10 years at minimum</time_frame>
    <description>Overall survival,both therapeutic policies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of invasive disease at the final pathology specimen (standard arm only)</measure>
    <time_frame>from inclusion till time of invasive disease during 10 years at minimum</time_frame>
    <description>Rate of invasive disease at the final pathology specimen (standard arm only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of grade III DCIS at the final pathology specimen (standard arm only)</measure>
    <time_frame>from inclusion till time of invasive disease during 10 years at minimum</time_frame>
    <description>Rate of grade III DCIS at the final pathology specimen (standard arm only)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>DCIS</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment according to local policy. This can be either wide local excision only, wide local excision and radiotherapy, or mastectomy. Hormonal therapy is also allowed.&#xD;
Follow-up:by annual digital mammography for a period of 5 years and a digital mammography at 7 and 10 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active surveillance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active surveillance : monitoring by annual digital mammography for a period of 5 years and a digital mammography at 7 and 10 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>wide local excision only or wide local excision and radiotherapy or mastectomy.&#xD;
+/- hormonal therapy</description>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>digital mammography</intervention_name>
    <description>annual mammography</description>
    <arm_group_label>Active surveillance</arm_group_label>
    <other_name>Active surveillance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>according local policy</description>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Written informed consent according to ICH GCP, and national andlocal regulations&#xD;
&#xD;
          -  Women ≥ 45 years old, any menopausal status&#xD;
&#xD;
          -  Unilateral DCIS grade I or II of any size&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) score 1 or 2 (see Appendix E)&#xD;
&#xD;
          -  Lesions of type 'calcifications only', detected by population-based or opportunistic&#xD;
             screening mammography&#xD;
&#xD;
          -  Within twelve weeks of detection, stereotactic biopsy has to be performed from the&#xD;
             area of the calcifications. Preferably vacuum assisted biopsies. Alternatively, at&#xD;
             least six 12 G needle biopsies (or the equivalent of six 12 G needles) may be used. )&#xD;
             . Whatever needle size is applied, it is essential to confirm that the biopsies&#xD;
             contain representative calcifications via biopsy radiography, microscopy, or both.&#xD;
&#xD;
          -  Estrogen receptor ≥ 80% positive and HER2 negative: 0 or 1+ or 2+ with negative ISH),&#xD;
             analysed centrally by pathology at NKI-AVL&#xD;
&#xD;
          -  In case of an extended lesion (&gt; 5 cm): biopsies were taken from the center and the&#xD;
             periphery of the lesion, or from two peripheral parts of the lesion&#xD;
&#xD;
          -  In case of multiple lesions with calcifications biopsies have been taken from two, but&#xD;
             not more, groups of calcifications&#xD;
&#xD;
          -  Marker placement at biopsy site (s) in the breast&#xD;
&#xD;
          -  FFPE tissue blocks from the biopsy and, if applicable, from the resection specimen,&#xD;
             are available for translational research purposes. If no FFPE tissue blocks can be&#xD;
             submitted, 10 unstained slides of 4-5 micrometer thickness from the lesion(s) are&#xD;
             acceptable&#xD;
&#xD;
          -  Good correlation between pathological and radiological findings i.e. both findings&#xD;
             confirm low-risk DCIS and no suspicion of high- grade DCIS or invasive breast cancer&#xD;
&#xD;
          -  The interval between histologic diagnosis of low-risk DCIS on biopsy and inclusion is&#xD;
             ≤ 12 weeks Exclusion criteria&#xD;
&#xD;
          -  Estrogen receptor negative: &lt;20% or HER2 positive: 3+, or 2+ with positive ISH&#xD;
&#xD;
          -  Presence of either mass, increased focal density or architectural distortion around&#xD;
             the calcifications on mammography (suspicious for invasive disease)&#xD;
&#xD;
          -  Presence of Paget's disease, invasive breast cancer, or pleomorphic LCIS; Lobular&#xD;
             neoplasia, referring to atypical lobular hyperplasia (ALH) and/or classic Lobular&#xD;
             Carcinoma In Situ according to the WHO Classification of Tumours of the Breast, is no&#xD;
             reason to exclude, whereas pleomorphic LCIS is&#xD;
&#xD;
          -  Symptomatic DCIS e.g. DCIS detected by palpation or bloody nipple discharge&#xD;
&#xD;
          -  Synchronous invasive carcinoma in the contralateral breast&#xD;
&#xD;
          -  Prior history of invasive breast cancer or DCIS, prior surgery because of benign&#xD;
             breast lesion (s) is allowed&#xD;
&#xD;
          -  Prior history of other malignancy (except non-melanoma skin cancer and carcinoma in&#xD;
             situ of the cervix) unless patient is discharged from follow-up for at least five&#xD;
             years.&#xD;
&#xD;
          -  Serious disease that precludes definitive surgical treatment (e.g cardiovascular/&#xD;
             pulmonary/ renal disease)&#xD;
&#xD;
          -  Individual with a family member with a known gene mutation associated with increased&#xD;
             risk of breast cancer, unless study participant is a proven non-carrier of mutation&#xD;
&#xD;
          -  Pregnancy or breast-feeding. Contraceptive measures during the trial are mandatory for&#xD;
             those patients that will participate in standard treatment arm and adequate counseling&#xD;
             should be provided by the treating physician. The duration of contraception will be&#xD;
             specified by the treating physician according to patient and treatment&#xD;
             characteristics, standard clinical practice and national regulations&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule; those conditions&#xD;
             should be discussed with the patient before registration in the trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jelle Wesseling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renee Schmitz, PhD student</last_name>
    <phone>+31 20512</phone>
    <phone_ext>7920</phone_ext>
    <email>r.schmitz@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carine Sondermeijer, Bsc</last_name>
    <phone>+31 20512</phone>
    <phone_ext>7423</phone_ext>
    <email>c.sondermeijer@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jan Palfijn</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vermeij</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Altintas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vermeij</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordet-Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Simon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Pierre</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nazac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Smeets</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Noordwest Ziekenhuisgroep- site Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gea Gooiker, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>van der Meij</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wesseling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate Ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Van Eekeren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexander Monro Ziekenhuis</name>
      <address>
        <city>Bilthoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Veenendaal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Luiten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Torrenga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slingeland Ziekenhuis</name>
      <address>
        <city>Doetinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Reijnders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Westenend</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>van Riet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maaskant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente Ariensplain</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>van Duyn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Linthorst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vuylsteke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis St. Jansdal</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Schouten van der Velden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vissers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bessems</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vuylsteke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westfriesgasthuis</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Govaert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Susanne H Estourgie, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diaconessenhuis Leiden</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Van Gijn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Liefers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis - Antoniushove</name>
      <address>
        <city>Leidschendam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jannink</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Smidt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Koelemij</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Strobbe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waterlandziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>De Widt-Levert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Obdeijn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zorgsaam Zeeuws-Vlaanderen</name>
      <address>
        <city>Terneuzen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Els van Dessel, Drs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jansen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>van Dalen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>van der Pol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum - Locatie Veldhoven</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maaskant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VieCuri - Medisch Centrum voor Noord-Limburg - Locatie Venlo</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aarts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zaans Medisch Centrum</name>
      <address>
        <city>Zaandam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelre ziekenhuizen</name>
      <address>
        <city>Zutphen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Truin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Noorda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, Pijnappel RM, Bijker N, Rutgers EJ, Wesseling J. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. Eur J Cancer. 2015 Aug;51(12):1497-510. doi: 10.1016/j.ejca.2015.05.008. Epub 2015 May 26.</citation>
    <PMID>26025767</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Women</keyword>
  <keyword>DCIS grade I and II</keyword>
  <keyword>Active surveillance</keyword>
  <keyword>Standard treatment</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

